Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
Sisi Wang1,2, Lijun Peng1,2, Wenqian Xu1,2, Yuebo Zhou1,2, Ziyan Zhu3, Yushan Kong4, Stewart Leung4, Jin Wang1,2(), Xiaoqiang Yan4(), Jian-Qing Mi1,2()
1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China 2. Pôle Franco-Chinois de Recherche en Sciences du Vivant et Genomique, Shanghai 200025, China 3. Shanghai Blood Center, Shanghai 200051, China 4. Generon Biomed, Shanghai 201210, China
The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. However, several studies showed that blinatumomab has a short plasma half-life due to its low molecular weight, and thus its clinical use is limited. Furthermore, multiple trials have shown that approximately 30% of blinatumomab-relapsed cases are characterized by CD19 negative leukemic cells. Here, we design and characterize two novel antibodies, A-319 and A-2019. Blinatumomab and A-319 are CD3/CD19 bispecific antibodies with different molecular sizes and structures, and A-2019 is a novel CD3/CD19/CD20 trispecific antibody with an additional anti-CD20 function. Our in vitro, ex vivo, and in vivo experiments demonstrated that A-319 and A-2019 are potent antitumor agents and capable of recruiting CD3 positive T cells, enhancing T-cell function, mediating B-cell depletion, and eventually inhibiting tumor growth in Raji xenograft models. The two molecules are complementary in terms of efficacy and specificity profile. The activity of A-319 demonstrated superior to that of A-2019, whereas A-2019 has an additional capability to target CD20 in cells missing CD19, suggesting its potential function against CD19 weak or negative CD20 positive leukemic cells.
AJ Grillo-López, CA White, BK Dallaire, CL Varns, CD Shen, A Wei, JE Leonard, A McClure, R Weaver, S Cairelli, J Rosenberg. Rituximab: the first monoclonal antibody approved for the treatment of lymphoma. Curr Pharm Biotechnol 2000; 1(1): 1–9 https://doi.org/10.2174/1389201003379059
pmid: 11467356
2
S Hipp, YT Tai, D Blanset, P Deegen, J Wahl, O Thomas, B Rattel, PJ Adam, KC Anderson, M Friedrich. A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 2017; 31(8): 1743–1751 https://doi.org/10.1038/leu.2016.388
pmid: 28025583
3
VA Guerra, EJ Jabbour, F Ravandi, H Kantarjian, NJ Short. Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia. Ther Adv Hematol 2019; 10: 2040620719849496 https://doi.org/10.1177/2040620719849496
pmid: 31205644
4
M Ruella, S Gill. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Expert Opin Biol Ther 2015; 15(6): 761–766 https://doi.org/10.1517/14712598.2015.1009888
pmid: 25640460
5
H Kantarjian, A Stein, N Gökbuget, AK Fielding, AC Schuh, JM Ribera, A Wei, H Dombret, R Foà, R Bassan, Ö Arslan, MA Sanz, J Bergeron, F Demirkan, E Lech-Maranda, A Rambaldi, X Thomas, HA Horst, M Brüggemann, W Klapper, BL Wood, A Fleishman, D Nagorsen, C Holland, Z Zimmerman, MS Topp. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 2017; 376(9): 836–847 https://doi.org/10.1056/NEJMoa1609783
pmid: 28249141
6
M Klinger, C Brandl, G Zugmaier, Y Hijazi, RC Bargou, MS Topp, N Gökbuget, S Neumann, M Goebeler, A Viardot, M Stelljes, M Brüggemann, D Hoelzer, E Degenhard, D Nagorsen, PA Baeuerle, A Wolf, P Kufer. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 2012; 119(26): 6226–6233 https://doi.org/10.1182/blood-2012-01-400515
pmid: 22592608
7
Y Cui, Z Huang, X Zhang, W Shen, H Chen, Z Wen, B Qi, L Luo, Y Tan, Y Wu, A Kung, X Yan. CD3-activating bi-specific antibody targeting CD19 on B cells in mono- and bi-valent format. Blood 2018; 132(Supplement 1): 4169 https://doi.org/10.1182/blood-2018-99-112819
8
M Ruella, DM Barrett, SS Kenderian, O Shestova, TJ Hofmann, J Perazzelli, M Klichinsky, V Aikawa, F Nazimuddin, M Kozlowski, J Scholler, SF Lacey, JJ Melenhorst, JJ Morrissette, DA Christian, CA Hunter, M Kalos, DL Porter, CH June, SA Grupp, S Gill. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 2016; 126(10): 3814–3826 https://doi.org/10.1172/JCI87366
pmid: 27571406
9
MS Topp, N Gökbuget, G Zugmaier, P Klappers, M Stelljes, S Neumann, A Viardot, R Marks, H Diedrich, C Faul, A Reichle, HA Horst, M Brüggemann, D Wessiepe, C Holland, S Alekar, N Mergen, H Einsele, D Hoelzer, RC Bargou. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32(36): 4134–4140 https://doi.org/10.1200/JCO.2014.56.3247
pmid: 25385737
10
MS Topp, N Gökbuget, G Zugmaier, E Degenhard, ME Goebeler, M Klinger, SA Neumann, HA Horst, T Raff, A Viardot, M Stelljes, M Schaich, R Köhne-Volland, M Brüggemann, OG Ottmann, T Burmeister, PA Baeuerle, D Nagorsen, M Schmidt, H Einsele, G Riethmüller, M Kneba, D Hoelzer, P Kufer, RC Bargou. Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL. Blood 2012; 120(26): 5185–5187 https://doi.org/10.1182/blood-2012-07-441030
pmid: 23024237
11
E Sotillo, DM Barrett, KL Black, A Bagashev, D Oldridge, G Wu, R Sussman, C Lanauze, M Ruella, MR Gazzara, NM Martinez, CT Harrington, EY Chung, J Perazzelli, TJ Hofmann, SL Maude, P Raman, A Barrera, S Gill, SF Lacey, JJ Melenhorst, D Allman, E Jacoby, T Fry, C Mackall, Y Barash, KW Lynch, JM Maris, SA Grupp, A Thomas-Tikhonenko. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov 2015; 5(12): 1282–1295 https://doi.org/10.1158/2159-8290.CD-15-1020
pmid: 26516065
12
E Zah, MY Lin, A Silva-Benedict, MC Jensen, YY Chen. T Cells expressing CD19/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res 2016; 4(6): 498–508 https://doi.org/10.1158/2326-6066.CIR-15-0231
pmid: 27059623
13
DA Thomas, S O’Brien, JL Jorgensen, J Cortes, S Faderl, G Garcia-Manero, S Verstovsek, C Koller, S Pierce, Y Huh, W Wierda, MJ Keating, HM Kantarjian. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009; 113(25): 6330–6337 https://doi.org/10.1182/blood-2008-04-151860
pmid: 18703706
14
S Raponi, MS De Propris, S Intoppa, ML Milani, A Vitale, L Elia, O Perbellini, G Pizzolo, R Foà, A Guarini. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011; 52(6): 1098–1107 https://doi.org/10.3109/10428194.2011.559668
pmid: 21348573
G Salles, M Barrett, R Foà, J Maurer, S O’Brien, N Valente, M Wenger, DG Maloney. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther 2017; 34(10): 2232–2273 https://doi.org/10.1007/s12325-017-0612-x
pmid: 28983798
17
DA Thomas, S O’Brien, S Faderl, G Garcia-Manero, A Ferrajoli, W Wierda, F Ravandi, S Verstovsek, JL Jorgensen, C Bueso-Ramos, M Andreeff, S Pierce, R Garris, MJ Keating, J Cortes, HM Kantarjian. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28(24): 3880–3889 https://doi.org/10.1200/JCO.2009.26.9456
pmid: 20660823
18
DT Teachey, SR Rheingold, SL Maude, G Zugmaier, DM Barrett, AE Seif, KE Nichols, EK Suppa, M Kalos, RA Berg, JC Fitzgerald, R Aplenc, L Gore, SA Grupp. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood 2013; 121(26): 5154–5157 https://doi.org/10.1182/blood-2013-02-485623
pmid: 23678006
19
PA Moore, W Zhang, GJ Rainey, S Burke, H Li, L Huang, S Gorlatov, MC Veri, S Aggarwal, Y Yang, K Shah, L Jin, S Zhang, L He, T Zhang, V Ciccarone, S Koenig, E Bonvini, S Johnson. Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma. Blood 2011; 117(17): 4542–4551 https://doi.org/10.1182/blood-2010-09-306449
pmid: 21300981
20
M Stanglmaier, M Faltin, P Ruf, A Bodenhausen, P Schröder, H Lindhofer. Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20×anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels. Int J Cancer 2008; 123(5): 1181–1189 https://doi.org/10.1002/ijc.23626
pmid: 18546289
21
MS Topp, N Gökbuget, AS Stein, G Zugmaier, S O’Brien, RC Bargou, H Dombret, AK Fielding, L Heffner, RA Larson, S Neumann, R Foà, M Litzow, JM Ribera, A Rambaldi, G Schiller, M Brüggemann, HA Horst, C Holland, C Jia, T Maniar, B Huber, D Nagorsen, SJ Forman, HM Kantarjian. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16(1): 57–66 https://doi.org/10.1016/S1470-2045(14)71170-2
pmid: 25524800
22
KR Parker, D Migliorini, E Perkey, KE Yost, A Bhaduri, P Bagga, M Haris, NE Wilson, F Liu, K Gabunia, J Scholler, TJ Montine, VG Bhoj, R Reddy, S Mohan, I Maillard, AR Kriegstein, CH June, HY Chang, AD Posey Jr, AT Satpathy. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 2020; 183(1): 126–142.e17 https://doi.org/10.1016/j.cell.2020.08.022
pmid: 32961131
MK Gleason, MR Verneris, DA Todhunter, B Zhang, V McCullar, SX Zhou, A Panoskaltsis-Mortari, LM Weiner, DA Vallera, JS Miller. Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production. Mol Cancer Ther 2012; 11(12): 2674–2684 https://doi.org/10.1158/1535-7163.MCT-12-0692
pmid: 23075808
